← Oncology Approval Tracker

FDA DECISION ·

Rylaze

asparaginase erwinia chrysanthemi (recombinant)-rywn · Jazz Pharmaceuticals

FDA approvalNew therapyAcute lymphoblastic leukemia and lymphoblastic lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Patients aged 1 month and older with acute lymphoblastic leukemia or lymphoblastic lymphoma and hypersensitivity to E. coli-derived asparaginase. Rylaze is part of multiagent chemotherapy.

LAMPGEN ANALYSIS

Why it matters

The recombinant product allows eligible patients to continue asparaginase therapy after hypersensitivity to another preparation.

What research teams should watch

Document the original product and reaction and recheck replacement dosing and administration dates.

PRIMARY RECORDS

Sources